-transparent.png){kind=logo}
The rate of chronic pancreas graft loss in simultaneous pancreas kidney transplantation has remained almost unchanged despite induction therapy. Since 1987, seven major immunosuppressive induction agents-basiliximab, daclizumab, ALG, eATG, OKT 3, alembuzumab, rATG-have been used as immunosuppressive induction agents. Those agents improved short-term survival by preventing acute rejection, but improvement of short-term survival has not translated into improved long-term graft survival. As with most solid organ transplants, there is a need for means to control chronic rejection to improve long-term graft survival.
Related Publications
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2009,
Clinical transplants,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
August 2010,
Diabetes care,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2008,
Clinical transplants,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2002,
Clinical nephrology,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2006,
Clinical transplants,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2012,
Clinical transplants,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2011,
Clinical transplants,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2015,
Clinical transplants,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2011,
Clinical transplants,
K Waki, and
Y Sugawara, and
S Tamura, and
N Yamashiki, and
H Fujita, and
T Kadowaki, and
N Kokudo
January 2006,
Clinical transplantation,
